EXTENDED REPORT

Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis

Estrella Garcia Gonzalez,1 Enrico Selvi,1 Epifania Balistrieri,1 Alfiya Akhmetshina,2 Katrin Palumbo,2 Sauro Lorenzini,1 Pietro Enea Lazzneri,3 Cinzia Montilli,3 Pier Leopoldo Capecchi,3 Monica Lucattelli,4 Caterina Baldi,1 Elena Gianchechi,3 Mauro Galeazzi,1 Franco Laghi Pasini,3 Jörg H W Distler2

ABSTRACT

Background Cannabinoids modulate fibrogenesis in scleroderma. Ajulemic acid (AjA) is a non-psychoactive synthetic analogue of tetrahydrocannabinol that can bind the peroxisome proliferator-activated receptor-γ (PPAR-γ). Recent evidence suggests a key role for PPAR-γ in fibrogenesis.

Objective To determine whether AjA can modulate fibrogenesis in murine models of scleroderma.

Material and methods Bleomycin-induced experimental fibrosis was used to assess the antifibrotic effects of AjA in vivo. In addition, the efficacy of AjA in pre-established fibrosis was assessed in a modified model of bleomycin-induced dermal fibrosis and in mice overexpressing a constitutively active transforming growth factor β (TGFβ) receptor I. Skin fibrosis was evaluated by quantification of skin thickness and hydroxyproline content. As a marker of fibroblast activation, α-smooth muscle actin was examined. To study the direct effect of AjA in collagen neosynthesis, skin fibroblasts from patients with scleroderma were treated with increasing concentrations of AjA. Protein expression of PPAR-γ, and its endogenous ligand 15d-PGJ2, and TGFβ were assessed before and after AjA treatment.

Results AjA significantly prevented experimental bleomycin-induced dermal fibrosis and modestly reduced its progression when started 3 weeks into the disease. AjA strongly reduced collagen neosynthesis by scleroderma fibroblasts in vitro, an action which was reversed completely by co-treatment with a selective PPAR-γ antagonist.

Conclusions AjA prevents progression of fibrosis in vivo and inhibits fibrogenesis in vitro by stimulating PPAR-γ signalling. Since therapeutic doses of AjA are well tolerated in humans, it is suggested that AjA as an interesting molecule targeting fibrosis in patients with scleroderma.

INTRODUCTION

Cannabinoids play key roles in several biological processes, including inflammation, immunomodulation and vasomotor responses.1 2 Moreover, the cannabinoid system might also be implicated in the pathogenesis of fibrosis.3 4 The endocannabinoid system comprises the two specific cannabinoid receptors, CB1 and CB2, their endogenous ligands and the machinery dedicated to endocannabinoid synthesis and degradation.5 In experimental models of dermal fibrosis, the CB1 and CB2 cannabinoid receptors modulate fibrogenesis by abrogating the underlying inflammation.6 7 In addition, cannabinoid agonists limit extracellular matrix (ECM) production by disrupting the transforming growth factor β (TGFβ) cascade, downregulating proliferation and activation of dermal fibroblasts.8 9 These data argue for a role of cannabinoids in limiting fibrosis, in addition to their anti-inflammatory and immunomodulatory effects. However, the precise molecular mechanisms remain to be elucidated.

Cannabinoids are not accepted widely as therapeutic agents owing to their psychoactive effects. Therefore, there is growing interest in development of synthetic compounds without cannabinomimetic activity on the central nervous system. Ajulemic acid (AjA; 1,1′-dimethylheptyl-tetrahydrocannabinol-11-oic acid) is a synthetic analogue of tetrahydrocannabinol, devoid of relevant psychotropic effects.10 It is a potent anti-inflammatory and analgesic agent in vivo.10 First data in humans indicate that AjA is well tolerated and can reduce chronic neuropathic pain without significant psychotropic effects in doses up to 80 mg/day.11 Although, AjA may be able to activate CB1-mediated central effects by crossing the blood–brain barrier in mice,12 the amount crossed seems not to be sufficient to trigger psychoactivity in humans.13 In addition to its affinity for CB1 and CB2 receptors, cannabinoids, including AjA, are an emerging new class of molecules that can bind to, and activate, the peroxisome proliferated-activated receptor-γ (PPAR-γ).14-17 PPAR-γ can be activated by some endocannabinoids and, in turn, PPAR-γ activation can modulate the endocannabinoid system, suggesting a reciprocal relationship.18

Indeed, the agonist effects of endocannabinoids on PPAR-γ may contribute to the regulatory effects of endocannabinoids on inflammation, and vasoactivity.10 Moreover, recent evidence suggests a key role for PPAR-γ in fibrogenesis. Suppression of PPAR-γ may contribute to the uncontrolled activation of fibroblasts.19 In fact, PPAR-γ and its natural occurring ligand 15-deoxy-A12,14-prostaglandin J2 (15d-PGJ2), exert antifibrotic effects by suppressing collagen production and fibroblast activation in bleomycin-induced fibrosis.20 21


1545
Since systemic sclerosis (SSc) is an autoimmune disease in which vascular injury and inflammation lead to progressive fibrosis of tissues,21 the cannabinoid system and PPAR-γ have been suggested as potential therapeutic targets. Considering that therapeutic doses of AJA simultaneously activate PPAR-γ and the cannabinoid system without affecting the central nervous system, we hypothesised that AJA might also be effective in preventing fibrosis in experimental models of SSc.

MATERIAL AND METHODS

Animal models of experimental dermal fibrosis
To assess in vivo the potential role of AJA as an antifibrotic agent, three different animal models were analysed. AJA was evaluated in bleomycin-induced dermal fibrosis, characterised primarily by inflammation, which typically occurs in the early phases of SSc. Skin fibrosis was induced in two groups of 6-week-old DBA/2J mice by local injection of bleomycin. Animals were treated with bleomycin alone (BLM group; n=8), bleomycin plus AJA 1 mg/kg-day (BLM/AJA group; n=8) and 0.9% NaCl saline solution (control group; n=8). Briefly, 100 μl of BLM dissolved in 0.9% NaCl at a concentration of 0.5 mg/ml was administered every other day, in well-defined areas (1 cm²) of the upper back.22 One group of BLM-challenged mice received orally AJA (JB Therapeutics, Newton, Massachusetts, USA) 1 mg/kg-day, dissolved in seed oil. Subcutaneous injections of 100 μl 0.9% NaCl were used as controls. After 21 days, animals were killed by cervical dislocation. The injected skin was removed and processed for analysis (see online supplementary text).

To test AJA on established fibrosis less dependent on inflammatory mechanisms, a modified model of bleomycin-induced dermal fibrosis was assessed,24 in which mice were challenged with bleomycin for 6 weeks and AJA treatment started during the last 3 weeks of bleomycin injections. Briefly, one group of mice was killed after receiving subcutaneous bleomycin injections for 6 weeks. The second group received bleomycin injections for 3 weeks followed by 0.9% NaCl injections for the next 3 weeks, to control for spontaneous regression of fibrosis. The third group was challenged with bleomycin for 6 weeks and was treated in parallel with AJA (1 mg/kg-day; oral administration) during the final 3 weeks of bleomycin injections. Two groups of mice, receiving subcutaneous injections of 100 μl 0.9% NaCl for 3 weeks and 6 weeks, respectively, were used as controls. The injected skin was removed and processed for analysis (see online supplementary text).

To assess the effect of AJA in a different model of sclerodermia fibrosis, a TGFβ-dependent model of dermal fibrosis was studied. Dermal fibrosis was induced in pathogen-free male C57BL/6 mice by intracutaneous injections of attenuated type V adenoviruses overexpressing a constitutively active TGFβ receptor I (AdTGFβR1) as described.25 Three groups of mice were analysed. One group was treated in parallel orally with AJA (1 mg/kg/day) for the last 4 weeks. Mice infected with attenuated type V adenoviruses encoding only for LacZ and sham treated with the solvent of AJA served as controls. Animals were killed after 8 weeks by cervical dislocation and back skin was removed for analysis (see online supplementary text).

Each treatment group consisted of eight mice. The local ethical committee approved all animal experiments.

Patients and fibroblast cultures
Dermal fibroblasts were obtained by a 5 mm punch biopsy from the leading edge of the affected skin on the forearm of five patients affected by diffuse cutaneous SSc (dcSSc) in the fibrotic phase. All patients fulfilled the criteria for dcSSc classification proposed by LeRoy et al.26 No patient was treated with an immunosuppressive agent or corticosteroids, nor were they taking cannabinoids for either recreational or therapeutic use at the time of biopsy (Table 1). Control fibroblasts were obtained from skin biopsy specimens from five healthy age- and sex-matched volunteers. Skin fibroblasts were expanded by outgrowth culture in Dulbecco’s modified Eagle’s medium (DMEM; Gibco Invitrogen, Grand Island, NY USA) as described previously.27 Fibroblasts from passages 3–6 were used for the experiments. All patients and healthy volunteers provided written informed consent using forms approved by the local institutional review boards.

Stimulation experiments
dcSSc and healthy dermal fibroblasts were cultured in DMEM containing 2.5% of fetal calf serum for 24 h before the experiments. Dermal fibroblasts were incubated with AJA (JB Therapeutics), dissolved in dimethyl sulphoxide at 0.1, 1, 5 and 10 μM concentrations for 24 h. Further experiments were performed by incubating dermal fibroblasts for 15 min before AJA treatment with the PPAR-γ irreversible antagonist GW9662 (Tocris Bioscience, Bristol, UK), at a concentration of 1 and 10 μM. (see online supplementary text).

Statistical analysis
Data are expressed as the mean±SD. Analysis of variance was used to compare multiple means, followed by the Student–Newman Keuls post hoc test (Sigma-StatV.3.5; Sigma Stat, Ashburn, Virginia, USA). p Values <0.05 were considered significant.

RESULTS

Ajulemic acid prevented bleomycin-induced dermal fibrosis in vivo
To evaluate the potential of AJA as an antifibrotic agent in vivo, we tested its efficacy in bleomycin-induced dermal fibrosis. Animals were treated with bleomycin alone (BLM group), bleomycin plus AJA 1 mg/kg-day (BLM/AJA group) and 0.9% NaCl saline solution (control group). After treatment, the BLM group and BLM/AJA group did not differ in body weight, and no other signs of toxicity of AJA such as ruffled fur or reduced activity were recorded.

Skin fibrosis was quantified at day 21 by determining dermal thickness and hydroxyproline content of lesional skin. Skin from the BLM group showed dense accumulation of ECM in the dermis and accumulation of inflammatory cells in the deeper dermal layers and perivascular spaces. In addition, the subcutaneous fat tissue was largely replaced by connective tissue. (figure 1A) A twofold increase in dermal thickness was seen in mice injected

<table>
<thead>
<tr>
<th>Table 1 Clinical and demographic characteristics of the patients with diffuse cutaneous systemic sclerosis (dcSSC)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Characteristics</td>
</tr>
<tr>
<td>Sex (M/F), n</td>
</tr>
<tr>
<td>Age, median (range), years</td>
</tr>
<tr>
<td>Disease duration, median (range), years†</td>
</tr>
<tr>
<td>Diffuse cutaneous disease</td>
</tr>
<tr>
<td>Number of Scl-70 positive</td>
</tr>
<tr>
<td>Potential disease-modifying agents</td>
</tr>
<tr>
<td>Prostacyclin analogues</td>
</tr>
<tr>
<td>Calcium channel blockers</td>
</tr>
<tr>
<td>Prokinetics</td>
</tr>
</tbody>
</table>

*dcSSc was determined according to LeRoy et al criteria.26
†From the first non-Raynaud’s manifestation.
Basic and translational research

with BLM compared with controls (p<0.001). Oral administration of AjA (1 mg/kg/day) prevented development of skin fibrosis, and reduced skin thickness nearly to control levels (p<0.001 compared with mock treated mice) (figure 1B). Furthermore, in the BLM/AjA group the subcutaneous leucocyte infiltration, the accumulation of ECM and the fat layer replacement were reduced (figure 1A).

Consistent with the histology, production of collagen, determined by quantification of dermal hydroxyproline content, was reduced substantially in mice treated with AjA (figure 1C). In the BLM group, levels of hydroxyproline were more than twofold greater than in controls (p<0.001). AjA treatment (1 mg/kg/day) completely abrogated the collagen deposition induced by BLM (p<0.001).

Myofibroblasts, characterised by the cytoskeletal protein α-smooth muscle actin, are considered one of the major cellular mediators of fibrosis in SSc. In BLM-challenged mice the number of α-smooth muscle actin-positive spindle-shaped fibroblastic cells per high-power field was increased twofold compared with controls (p<0.001). AjA treatment significantly reduced the number of myofibroblasts in lesional skin up to 26±5% (mean±SD) (p<0.001) (figure 1D).

Ajulemic acid reduced progression of fibrosis in vivo

To assess whether AjA is effective in an in vivo model of dermal fibrosis that is largely independent of autoimmune and inflammatory phenomena, we tested its efficacy in the constitutively active TGFβ receptor type 1 mouse model (AdTGFβRI). AdTGFβRI mice are characterised by generalised dermal fibrosis and fibroblast-specific activation of TGFβ signalling. After 8 weeks AdTGFβRI mice showed twofold increase in dermal thickness compared with AdLacZ control mice (p<0.05). Oral administration of AjA (1 mg/kg/day) for the last 4 weeks reduced development of skin thickness up to 30±6% (mean±SD) compared with AdTGFβRI mice (p<0.05) (figure 2A,B). AjA treatment (1 mg/kg/day) induced a mean reduction of 30±13% (mean±SD) in hydroxyproline content (p<0.05) (figure 2C). AjA treatment also significantly reduced the number of myofibroblasts in lesional skin up to 26±3% (p<0.001) (figure 2D).

To further evaluate the efficacy of AjA for the treatment of established fibrosis, we used a 6-week model of bleomycin-induced dermal fibrosis. Consistent with previous studies, dermal thickness increased by 76±4% (mean±SD) (p<0.05 vs NaCl controls) after 6 weeks of treatment with bleomycin. To assess the effects of AjA, mice challenged with bleomycin for 6 weeks were treated in parallel with AjA (1 mg/kg/day) during the final 3 weeks of bleomycin injections. Dermal thickness in mice treated with AjA for the last 3 weeks was reduced by 11±17% (mean±SD) compared with 6-week bleomycin-challenged mice (p<0.05). Furthermore, dermal thickness in mice treated with AjA did not differ significantly from mice challenged with bleomycin for...
Basic and translational research

Figure 2  Antifibrotic effects of ajulemic acid (AjA) in AdTGFβRI mice. (A) Dermal fibrosis in AdTGFβRI mice treated with AjA (1 mg/kg/day) was reduced compared with mock-treated mice. Haematoxylin and eosin staining. Original magnification ×10. (B) Histograms showing a significant reduction in dermal thickness of AdTGFβRI lesional skin after AjA treatment. (C) Hydroxyproline content of AdTGFβRI lesional skin was reduced after AjA treatment. (D) Histograms showing significant reduction in α-smooth muscle actin (α-SMA)-positive spindle-shaped fibroblastic cells per microscopic high field after AjA treatment of AdTGFβRI mice. Each treatment group, n=8. All values are mean±SD. Analysis of variance was used to compare multiple means, followed by the Student–Newman Keuls post hoc test for multiple comparisons.

Figure 3  Ajulemic acid (AjA) inhibits progression of dermal fibrosis in a modified model of 6 weeks bleomycin (BLM)-induced fibrosis. (A) Treatment with AjA (1 mg/kg/day) prevented further matrix accumulation, but did not induced regression of pre-existing fibrosis. Haematoxylin and eosin staining. Original magnification ×10. (B) Treatment with AjA reduced dermal thickness of lesional skin for the last 3 weeks. (C) Histograms showing hydroxyproline content of lesional skin. AjA treatment disrupted collagen deposition for the last 3 weeks, without regression of pre-existing extracellular matrix accumulation. (D) Histograms showing a significant reduction in the number of α-smooth muscle actin (α-SMA)-positive spindle-shaped fibroblastic cells per microscopic high field after treatment with AjA. Each treatment group, n=8. All values are mean±SD. Analysis of variance was used to compare multiple means, followed by the Student–Newman Keuls post hoc test for multiple comparisons.
3 weeks (figure 3A,B). Consistently, a twofold increase of levels of hydroxyproline was recorded in the 6-week bleomycin-challenged group compared with controls (p<0.001). AjA treatment for the last 3 weeks reduced collagen deposition by 10±8% (mean±SD) (p<0.05). Thus, AjA administration for the last 3 weeks of bleomycin challenge stopped further progression of fibrosis, but did not alter pre-existing ECM accumulation (figure 3C). The number of myofibroblasts after AjA treatment was significantly reduced in lesional skin up to 25±16% (mean±SD) compared with bleomycin-challenged mice (p<0.05) (figure 3D).

Ajulemic acid inhibited collagen neosynthesis in dcSSc fibroblasts through PPAR-γ

To investigate whether AjA directly inhibits collagen synthesis in cultured fibroblasts, we quantified the levels of procollagen type I propeptide (PIP) in supernatant from dcSSc and healthy cultured fibroblasts with AjA. AjA (0.1 to 10 μM) reduced the levels of PIP released from dcSSc fibroblasts in a dose-dependent manner. Maximal inhibition was observed at 10 μM concentration with a mean PIP reduction up to 60±7% (p<0.001) (figure 4). Similar results were seen in healthy dermal fibroblasts (data not shown).

AjA did not exert toxic effects on fibroblasts at the concentrations used. The metabolic activity measured by the MTT assay was not affected by treatment with AjA in concentrations up to 10 μM (data not shown).

To evaluate a PPAR-γ pathway dependency, dcSSc and healthy fibroblasts treated with AjA were preincubated with the highly selective PPAR-γ antagonist GW9662 (1–10 μM). The inhibitory effect of AjA on collagen production was completely prevented by GW9662 at 10 μM concentration (p<0.05) (figure 5A).

In addition, we analysed the effect of AjA on expression of the endogenous PPAR-γ ligand 15d-PGJ2. The levels of 15d-PGJ2 were reduced in supernatants of dcSSc fibroblasts compared with controls (p<0.001). However, incubation with AjA strongly increased the levels of 15d-PGJ2 in a dose-dependent manner (p<0.001) (figure 5B).

Further, we assessed PPAR-γ expression in dcSSc and healthy fibroblasts. The protein levels of PPAR-γ were reduced in dcSSc fibroblasts compared with healthy controls. However, treatment with AjA (5 μM and 10 μM) significantly increased the expression of PPAR-γ in dcSSc fibroblasts (p<0.001) (figure 5C).
Results of experiments presented here indicate that AjA efficiently reduces collagen production through PPAR-γ activation, and in vivo reduced dermal fibrosis in the constitutively active TGFβ receptor type I mouse model (AdTGFβRI), we evaluated its ability to downregulate TGFβ in vitro. TGFβ concentrations in supernatants from dcSSc fibroblasts were significantly higher than TGFβ concentrations in supernatants from healthy controls (p<0.001). Upon incubation with AjA, a significant dose-dependent reduction in TGFβ concentrations (up to 50%) was seen in supernatants from dcSSc fibroblasts (p<0.001), with maximum suppression seen at 2 h (figure 6).

DISCUSSION

Results of experiments presented here indicate that AjA efficiently prevents bleomycin-induced dermal fibrosis in mice. In addition, this cannabinoid can inhibit progression of ECM deposition in animal models of established skin fibrosis. In dcSSc fibroblasts, AjA inhibits collagen synthesis through activation of PPAR-γ.

Modulation of the CB1 and CB2 receptors limits skin fibrosis by reducing inflammation.6 7 Although the synthetic tetrahydrocannabinol analogue AjA is a weak ligand of the classical cannabinoid receptors CB1 and CB2,10 we suggest that AjA may also act to reduce fibrosis directly through a PPAR-γ-mediated mechanism. Consistent with this notion are data which indicate that the high-affinity cannabinoid receptor agonist WIN55, 212-2 exerts antifibrotic effects that are not mediated by the classic cannabinoid receptors.9 10 A close relationship between the endocannabinoid system and PPAR-γ signalling has been postulated.18 Accumulating evidence suggests that impaired expression and function of PPAR-γ is important in the pathogenesis of fibrosis in SSc.28 Such diminished activity is counterbalanced by uncontrolled TGFβ signalling, thereby triggering fibrogenesis.29 Cross-talk between these two mediators orchestrates the mechanisms of normal wound healing.20

The activation of PPAR-γ by its natural ligands controls fibrotic responses. PGJ2 in a physiological condition increases during the resolution phase of wound healing by blocking fibroblast activation and collagen neosynthesis.28 Upon chronic fibrogenic stimulation the expression and function of PPAR-γ are reduced, leading to unbalanced collagen neosynthesis driven by TGFβ signalling. Accordingly, PPAR-γ activation by PGJ2 results in a robust reduction of inflammatory infiltrates and progression of fibrosis in murine models of bleomycin-induced fibrosis.21

Consistent with these findings, we observed that the increased release of TGFβ is mirrored by a concomitant decrease of PPAR-γ. We demonstrate that AjA reduces release of TGFβ from dcSSc fibroblasts and that AjA can counteract the progression of fibrosis in vivo in an overactivated TGFβ pathway mouse model. Moreover, AjA also stimulates expression of the endogenous PPAR-γ ligand PGJ2. By inhibiting TGFβ and stimulating the release of PGJ2, AjA probably promotes PPAR-γ signalling in dcSSc fibroblasts.

We also show that oral administration of AjA attenuates markedly the dermal fibrosis induced in DBA/2J mice by bleomycin. AjA reduces fibroblast activation, ECM deposition, and subsequent dermal thickening. Bleomycin-induced dermal fibrosis is considered a reliable experimental model for SSc that reflects the early stages of the disease, with increased deposition of collagen and other ECM components, migration of inflammatory cells into the skin and atrophy of the adipose tissue.30 It is still unclear why in SSc, atrophy of the fat tissue occurs, in favour of connective tissue replacement. However, recent data suggest that PPAR-γ might play a central role in regulating the balance between adipogenesis and fibrogenesis.39 Accumulating evidence suggests that increased activation of PPAR-γ favours adipogenesis, whereas decreased PPAR-γ favours tissue fibrosis. According to this model, the downregulation of PPAR-γ seen in SSc would enhance recruitment of mesenchymal precursors, stimulate release of collagen from resident fibroblasts and inhibit adipogenic differentiation.19 In accordance, reduction of PPAR-γ in Wnt-10b-transgenic mice suppresses adipogenesis while promoting reciprocal fibrogenesis.43 Consistent with this hypothesis, AjA stimulates the differentiation of embryonic fibroblastic ST3 L1 cells into adipocytes, a process that is known to be mediated by PPAR-γ.10 Based on these results, we suggest that AjA might exert its antifibrotic effects by restoring the defective PPAR-γ activation in dcSSc fibroblasts. We observed that AjA stimulates the expression of PPAR-γ in dcSSc fibroblasts, upregulating expression of its endogenous ligand 15d-PGJ2. We showed that activation of PPAR-γ is essential for the antifibrotic effects of AjA in vitro and that inhibition of PPAR-γ disrupts the inhibitory effects of AjA on collagen synthesis. In addition, treatment of bleomycin-challenged mice with AjA prevents fibrosis and also the characteristic atrophy of the subcutis.
Results of the studies presented in this paper show that AjA reduces infiltration of the dermis by inflammatory cells. Since the mouse model of bleomycin-induced fibrosis is responsive to anti-inflammatory drugs, it could be argued that AjA reduces progression of fibrosis in vivo. We also observed direct anti-fibrotic effects of AjA in in vivo models largely independent of inflammation—for example, in mice overexpressing a constitutively active TGFβ receptor I. Moreover, in murine models of established fibrosis, we demonstrated that AjA reduces progression of fibrosis. However, treatment with AjA does not induce regression of pre-existing fibrosis in these models.

In conclusion, we demonstrate that AjA exerts potent anti-fibrotic effects in vivo, which in vitro are mediated by PPAR-γ signalling. Cannabinoids and PPAR-γ agonists might be ideal drugs to target SSc since they can modulate fibrosis, inflammation and vasodilatation, all of which are dysregulated in SSc. Our findings have direct translational implications, because a proof-of-concept trial with AjA for the treatment of SSc is in preparation.

Acknowledgements The authors are grateful to Professor Robert B Zurier, MD, Professor of Medicine, University of Massachusetts Medical School (Worcester, Massachusetts, USA), for advice and critical reading of the manuscript. The authors thank JB Therapeutics (Massachusetts, USA) which kindly provided ajulemic acid for all the experiments presented in this paper.

Contributors (1) Guarantor of integrity of the entire study: Egg, ES, JHWD; (2) study concept and design: Egg, ES, JHWD; (3) literature research: Egg, ES, PFL, PLC, MG, FLF; (4) in vivo and in vitro experiments: EB, AA, KP, Sl, CM, ML, ED; (5) data collection and interpretation: Egg, ES, EB, CB; (6) statistical analysis: Egg, ES, CB; (7) manuscript editing: Egg, ES, JHWD, MG, PFL, PLC; (8) final approval of manuscript: Egg, ES, JHWD, FLF, MG, PFL, PLC, EB, AA, KP, Sl, CB, CM, ML, EG

Competing interests None.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis

Estrella Garcia Gonzalez, Enrico Selvi, Epifania Balistreri, Alfiya Akhmetshina, Katrin Palumbo, Sauro Lorenzini, Pietro Enea Lazzerini, Cinzia Montilli, Pier Leopoldo Capecchi, Monica Lucattelli, Caterina Baldi, Elena Gianchecchi, Mauro Galeazzi, Franco Laghi Pasini and Jörg H W Distler

Ann Rheum Dis 2012 71: 1545-1551 originally published online April 4, 2012
doi: 10.1136/annrheumdis-2011-200314